Peter MacCallum Cancer Centre
Research facility
Location:
Melbourne,
Australia (AU)
ISNI: 0000000403978434
ROR: https://ror.org/02a8bt934
Show on Map:
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer (2014)
Loibl S, Von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, et al.
Journal article
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study (2014)
Koebel M, Madore J, Ramus SJ, Clarke BA, Pharoah PDP, Deen S, Bowtell DD, et al.
Journal article
Autophagy Induction Is a Tor- and Tp53-Independent Cell Survival Response in a Zebrafish Model of Disrupted Ribosome Biogenesis (2013)
Boglev Y, Badrock AP, Trotter AJ, Du Q, Richardson EJ, Parslow AC, Markmiller SJ, et al.
Journal article
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer (2013)
Pharoah PDP, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, et al.
Journal article
Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer (2009)
Birkholz K, Hombach A, Krug C, Reuter S, Kershaw M, Kämpgen E, Schuler G, et al.
Journal article